MeCure Industries targets N14 billion in Series 8 commercial paper issuance

MeCure Industries Plc has initiated an offer for up to N14 billion in Series 8 Commercial Paper as part of its N40 billion Commercial Paper Programme. This Lagos-based pharmaceutical manufacturer utilizes the market to secure funds for its short-term working capital requirements. The offer features an implied annual yield of 21%.

Investors who hold the paper for its full 267-day tenure would earn around 15.36% on their investment, before any deductions, assuming full repayment by MeCure. The offering commenced on Wednesday, October 14, 2026, and will conclude on Tuesday, October 20, 2026.

This announcement follows MeCure's February 2026 series of a N10 billion Series 7 commercial paper, which boasted a gross annualised yield of 21.75%. For every N5 million invested, MeCure's 21% annual yield would have generated approximately N768,000 in gross income over 267 days, calculated using a 365-day basis. The total proceeds from this offer would be roughly N5.768 million, excluding applicable deductions, provided MeCure fulfills its repayment obligations.

MeCure's 21% annual yield surpasses the yields of six-month and one-year Treasury bills, which stood at 17.16% and 18.91% respectively, during the October 14 auction. MeCure's assurance lies in its successful repayment of a N3 billion bond in April 2026, coupled with its expanding business operations. Revenue rose by 20.4% to N44.85 billion in H1 2026, while operating profit increased by 41% to N10.90 billion, despite higher marketing expenses.

The new facilities may help alleviate the pressure on operating profits if they generate sufficient additional sales and cash to offset the associated costs.

For commercial paper (CP) investors, repayment confidence hinges on the timely cash inflows and the availability of funding when the paper matures. The offer provides a gross annualised yield of 21%, which translates to approximately 15.36% over the 267-day period. Investors must verify the net income after deductions and align their investment plans with the July 2027 maturity date.

Key factors to consider include rising financing costs, the capital committed to expansion, and the timing of customer payments. A consistent cash generation ability and a clear repayment funding strategy would provide additional reassurance along with MeCure's consistent earnings growth and favorable credit ratings.